下尿路症状与良性前列腺增生的联合药物治疗
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia.
作者信息
Roehrborn Claus G
出版信息
Rev Urol. 2005;7 Suppl 8(Suppl 8):S43-51.
Abstract
Medical therapy with alpha-adrenergic receptor blockers and 5-alpha-reductase inhibitors is currently considered first-line treatment for men with moderate to severe symptoms of benign prostatic hyperplasia (BPH). Given the success that has been realized with monotherapy with each of these agents, interest in combination therapy has grown. Large-scale trials to test the efficacy of such combinations are lacking; however, a few studies, such as the Medical Therapy of Prostatic Symptoms trial, have yielded results indicating that the 2 types of agents combined can reduce the risk of symptomatic progression and acute urinary retention, as well as the need for invasive therapy. More research is needed to clarify the roles of these agents in the treatment of BPH and in the optimization of patient quality of life.
摘要
α-肾上腺素能受体阻滞剂和5-α还原酶抑制剂的药物治疗目前被认为是治疗中度至重度良性前列腺增生（BPH）症状男性的一线治疗方法。鉴于使用这些药物单一疗法已取得成功，人们对联合治疗的兴趣与日俱增。缺乏大规模试验来测试此类联合治疗的疗效；然而，一些研究，如前列腺症状医学治疗试验，已得出结果表明，这两种药物联合使用可降低症状进展和急性尿潴留的风险，以及侵入性治疗的必要性。需要更多的研究来阐明这些药物在BPH治疗和优化患者生活质量方面的作用。
相似文献
1
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia.
Rev Urol. 2005;7 Suppl 8(Suppl 8):S43-51.
2
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0.
3
The role of combination medical therapy in benign prostatic hyperplasia.
Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
4
The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Prostate. 2021 Sep;81(13):944-955. doi: 10.1002/pros.24190. Epub 2021 Jul 20.
5
Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Arch Ital Urol Androl. 2009 Mar;81(1):1-8.
6
A review of combination therapy in patients with benign prostatic hyperplasia.
Clin Ther. 2007 Mar;29(3):387-98. doi: 10.1016/s0149-2918(07)80077-4.
7
Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Eur Urol. 2017 Apr;71(4):570-581. doi: 10.1016/j.eururo.2016.09.032. Epub 2016 Oct 4.
8
Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Curr Pharm Des. 2006;12(7):775-83. doi: 10.2174/138161206776056010.
9
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
BJU Int. 2019 Jul;124(1):27-34. doi: 10.1111/bju.14689. Epub 2019 Mar 11.
10
Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
Drugs Today (Barc). 2016 Sep;52(9):501-517. doi: 10.1358/dot.2016.52.9.2525739.
引用本文的文献
1
Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
Prostate Cancer Prostatic Dis. 2024 Sep;27(3):469-477. doi: 10.1038/s41391-023-00731-w. Epub 2023 Oct 4.
2
The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.
Cancers (Basel). 2023 Jun 8;15(12):3110. doi: 10.3390/cancers15123110.
3
NF-κB and androgen receptor variant expression correlate with human BPH progression.
Prostate. 2016 Apr;76(5):491-511. doi: 10.1002/pros.23140. Epub 2015 Dec 28.
4
Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.
Int J Mol Sci. 2013 Jul 10;14(7):14301-20. doi: 10.3390/ijms140714301.
5
Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense?
Curr Urol Rep. 2007 Jul;8(4):289-97. doi: 10.1007/s11934-007-0075-8.
本文引用的文献
1
II. The Question of Castration for Enlarged Prostate.
Ann Surg. 1896 Sep;24(3):265-309. doi: 10.1097/00000658-189607000-00036.
2
I. The Results of Double Castration in Hypertrophy of the Prostate.
Ann Surg. 1895 Jul;22(1):1-80. doi: 10.1097/00000658-189507000-00001.
3
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656.
4
AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.
J Urol. 2003 Aug;170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.
5
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.
Control Clin Trials. 2003 Apr;24(2):224-43. doi: 10.1016/s0197-2456(02)00263-5.
6
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
Urology. 2003 Jan;61(1):119-26. doi: 10.1016/s0090-4295(02)02114-3.
7
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Urology. 2002 Sep;60(3):434-41. doi: 10.1016/s0090-4295(02)01905-2.
8
Combination medical therapy for symptomatic benign prostatic hyperplasia.
Can J Urol. 1998 Aug;5(3):578-584.
9
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
J Urol. 2000 Apr;163(4):1134-7.
10
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Eur Urol. 1999;36(1):1-13. doi: 10.1159/000019919.
Zotero 插件